Search
forResearch 10 of 1000+
- Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review
- Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
- Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review
- Hidradenitis suppurativa: A comparison of guidelines
- Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
- Management of ‘refractory’ skin disease in patients with lupus erythematosus
- Cronkhite-Canada syndrome: An elusive gastrointestinal disorder with multisystem involvement-pathogenesis, diagnosis, and therapeutic strategies
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
Community 2 of 4
- Why hasn’t anyone made a "DHT sponge" biologic yet???
- HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Learn
— no results
Try a deeper search in learn →